CJC-1295 vs Sermorelin：生长激素肽比较
快速摘要
- CJC-1295 is a modified GHRH analog available in two forms: with DAC (Drug Affinity Complex, extending half-life to 6-8 days) and without DAC (also called Mod GRF 1-29, half-life ~30 minutes).
- Sermorelin is a 29-amino-acid GHRH analog with a short half-life of approximately 10-20 minutes, closely mimicking natural pulsatile GH release.
- Key difference: CJC-1295 with DAC creates sustained GH elevation; sermorelin and CJC-1295 without DAC produce more physiological pulsatile patterns.
- Clinical status: Sermorelin was previously FDA-approved (Geref) but discontinued commercially. CJC-1295 remains a research compound.
- Researcher preference: Varies by study design. Sermorelin is preferred for studies requiring pulsatile release; CJC-1295 with DAC for sustained elevation protocols.
Introduction: Two Approaches to GH Stimulation
CJC-1295 and sermorelin are both analogs of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary to produce and release growth hormone. While they share the same fundamental target, their pharmacokinetic profiles differ dramatically, leading to distinct patterns of GH release. This comparison examines the research evidence for each compound, helping researchers understand which analog best fits different experimental designs.
For background on these peptides, see our articles on CJC-1295 and Ipamorelin and Sermorelin.
Comparison Table
| Property | CJC-1295 (with DAC) | CJC-1295 (no DAC / Mod GRF 1-29) | Sermorelin |
|---|---|---|---|
| Amino Acid Length | 30 amino acids + DAC | 29 amino acids (modified) | 29 amino acids |
| Half-Life | 6-8 days | ~30 minutes | ~10-20 minutes |
| GH Release Pattern | Sustained elevation (non-pulsatile) | Pulsatile (when dosed intermittently) | Pulsatile (mimics natural rhythm) |
| Dosing Frequency | 1-2 times per week | 1-3 times daily | 1-2 times daily |
| IGF-1 Elevation | Sustained increase (2-10x over baseline in studies) | Transient increase per dose | Transient increase per dose |
| Pituitary Desensitization Risk | Higher (due to continuous stimulation) | Lower | Lowest |
| Selectivity | GH only (no cortisol/prolactin effects) | GH only (no cortisol/prolactin effects) | GH only (no cortisol/prolactin effects) |
| FDA History | Never approved; research compound | Never approved; research compound | Previously approved as Geref (discontinued 2008) |
| DAC Modification | Yes (covalent albumin binding) | No | No |
| Common Research Pairings | Sometimes combined with GHRP for synergy | Often paired with Ipamorelin or GHRP-2 | Often used alone or with GHRP-6 |
Understanding the DAC Distinction
The most critical distinction in this comparison is the Drug Affinity Complex (DAC) modification available for CJC-1295. DAC is a reactive chemical group (maleimidopropionic acid) that forms a covalent bond with albumin after injection. This albumin binding dramatically extends the half-life from approximately 30 minutes (without DAC) to 6-8 days (with DAC), fundamentally changing the pharmacodynamic profile.
CJC-1295 with DAC produces a sustained elevation of GH and IGF-1 levels. In clinical studies by ConjuChem Biotechnologies, a single 60 mcg/kg injection produced IGF-1 elevations lasting 9-11 days, with GH levels remaining elevated for 6-8 days. This sustained profile is convenient for dosing compliance but does not mimic the natural pulsatile pattern of GH release.
CJC-1295 without DAC (commonly called Mod GRF 1-29 or simply CJC-1295 no DAC) retains four amino acid substitutions that protect against enzymatic degradation but lacks the albumin-binding modification. Its ~30-minute half-life produces acute GH pulses similar to but longer than natural GHRH. This allows researchers to study more physiological GH pulsatility patterns.
Sermorelin: The Established GHRH Analog
Sermorelin acetate (GRF 1-29 NH2) represents the first 29 amino acids of the 44-amino-acid native GHRH sequence. It was the first GHRH analog to receive FDA approval (as Geref) for the diagnosis and treatment of growth hormone deficiency in children, though it was commercially discontinued in 2008 due to manufacturing and supply issues rather than safety concerns.
Sermorelin's short half-life (10-20 minutes) means it produces the most physiological GH release pattern among the three analogs, closely mimicking the acute GHRH pulses produced by the hypothalamus. This pulsatile pattern is considered important because the body's GH-responsive tissues evolved to respond to intermittent GH exposure, and continuous GH elevation may lead to receptor desensitization.
One of sermorelin's advantages from a research standpoint is its established safety record from years of clinical use and its well-characterized pharmacology. Its limitations include its very short half-life requiring frequent administration and its susceptibility to enzymatic degradation.
Mechanism of Action: Shared and Divergent
All three compounds activate the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland. This activation triggers a signaling cascade involving cAMP that stimulates both the synthesis and release of growth hormone. The key mechanistic differences lie in their pharmacokinetics rather than their receptor pharmacology:
- Duration of receptor stimulation: CJC-1295 with DAC provides continuous stimulation; the others provide intermittent pulses.
- Somatostatin interaction: The pulsatile peptides (sermorelin, CJC-1295 no DAC) are subject to natural somatostatin feedback, which limits GH release during somatostatin-dominant periods. CJC-1295 with DAC partially overcomes this through sustained receptor occupancy.
- Desensitization dynamics: Continuous GHRH-R stimulation from CJC-1295 with DAC may lead to receptor desensitization over time, potentially reducing efficacy with prolonged use. The pulsatile agents preserve receptor sensitivity through intermittent stimulation and recovery periods.
Best Research Applications
Winner for Pulsatile GH Research: Sermorelin
When the research question requires mimicking natural GH pulsatility, sermorelin's short half-life and established pharmacology make it the preferred choice. Its prior FDA approval also provides a more extensive human safety dataset for reference.
Winner for Convenience and Sustained GH Elevation: CJC-1295 with DAC
For protocols requiring sustained GH and IGF-1 elevation with minimal dosing frequency, CJC-1295 with DAC offers the longest duration of action. This makes it suitable for studies examining the effects of chronic GH elevation.
Winner for Combination Protocols: CJC-1295 without DAC (Mod GRF 1-29)
The most popular research pairing in the growth hormone peptide space is CJC-1295 without DAC combined with Ipamorelin. This combination leverages synergy between GHRH receptor activation and ghrelin receptor (GHS-R) activation, producing amplified GH pulses while maintaining pulsatility and selectivity. The ~30-minute half-life is long enough to pair conveniently with GHRP compounds but short enough to preserve pulsatile release dynamics.
Winner for Safety Data: Sermorelin
With its history of FDA approval and years of clinical use in pediatric growth hormone deficiency, sermorelin has the most comprehensive human safety dataset. CJC-1295 has limited Phase 2 clinical data, and its safety profile is less thoroughly characterized.
For a broader overview of growth hormone secretagogues, see our Complete Guide to Growth Hormone Secretagogues.
Educational Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. The peptides discussed are research compounds (CJC-1295) or previously approved medications now used off-label (sermorelin). Always consult with qualified healthcare professionals and ensure compliance with all applicable regulations.
免责声明： 本文仅供参考和教育目的，不构成医疗建议、诊断或治疗。在做出关于多肽使用或任何健康相关方案的决定之前，请务必咨询合格的医疗专业人员。
获取每周多肽研究动态
最新的多肽研究、指南和见解直接发送到您的收件箱。
无垃圾邮件，随时退订。